WillItSurvive
Pharma and healthcare groups · United States

AbbVie

abbvie.com ↗

AbbVie is a US pharma giant selling immunology drugs like Skyrizi and Rinvoq.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from July 31, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report showing whether immunology growth is slowing
The call

AbbVie already replaced its biggest drug with two faster growing ones and keeps expanding despite rivals and a 2027 patent cliff ahead.

AbbVie is a pharmaceutical company that makes prescription drugs for immune system and cancer conditions. The company did something unusual: when its top-selling drug Humira lost patent protection and sales fell by nearly half, two new drugs called Skyrizi and Rinvoq grew so fast they more than made up for the loss, pushing the company to record revenue in 2025. Rivals like J&J and Eli Lilly have launched competing drugs in the same space, and AI companies are getting better at discovering new drug candidates, but neither threat is close to taking over AbbVie's business right now because making a drug requires not just discovery but FDA approval, years of testing, doctor relationships, insurance company deals, and manufacturing infrastructure that take a decade to build. The one thing that could hurt AbbVie is if Rinvoq's patent protections end sooner than expected around 2027, or if government price controls expand to cover its newest drugs as they age.

Why
01
AI pressure: Insilico Medicine / AlphaFold3 style AI drug discovery tools. AI speeds up drug discovery for AbbVie and rivals alike, but FDA approval, trials, and payer deals stay the real gatekeepers. Could AI do the core job? Unlikely.
02
Bigger players: J&J (Tremfya), Sanofi/Regeneron (Dupixent), Eli Lilly (Ebglyss). All three have shipped competing immunology drugs, yet Skyrizi still grew nearly 50% in 2025 and Rinvoq kept expanding. Could a giant copy it? No, they are blocked.
03
What protects it. Patent exclusivity, FDA approval, and locked-in payer and PBM contracts keep Skyrizi and Rinvoq from being copied fast.
What would change this call
Skyrizi or Rinvoq quarterly growth rate visibly slows or turns negative in an upcoming earnings report. Would show Dupixent or Ebglyss are actually taking share, not just competing.
Rinvoq patent extensions via formulation or method-of-use filings are granted or rejected before 2027. Would show whether AbbVie can delay biosimilar entry on its second-largest drug.
Medicare IRA pricing negotiations add Skyrizi or Rinvoq to controlled-price lists before 2030. Would show government pricing pressure cutting into AbbVie's newest growth drivers.
Key numbers
  • FY2025 revenue $61.16B, up 8.6% (2026-02-04)
  • Skyrizi sales $17.6B, up 49.9% (2026-02-04)
  • Market cap about $450B (2026-07-20)
Named risks
  • Rinvoq core patent expiring around 2027 without secured formulation/method-of-use bridge. Severity: high
  • IRA Medicare pricing pressure hitting Imbruvica in 2026, expanding toward Skyrizi/Rinvoq over time. Severity: medium
  • Trump administration MFN pricing/tariff exemption expires in 2029 with pending Supreme Court tariff ruling. Severity: medium
  • Continued Humira biosimilar erosion, down 49.5% in FY2025. Severity: medium
  • Pending $180M opioid-related third-party-payor settlement fairness hearing set for September 23, 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Johnson & JohnsoncontestingTremfya/Stelara compete in immunology; J&J posted $94.2B revenue in 2025 vs AbbVie's $61.2B
Sanofi/Regeneron (Dupixent)contestingDupixent growing and directly rivals Skyrizi/Rinvoq, though AbbVie still grew +49.9% (2025)
Eli Lilly (Ebglyss)contestingEbglyss competes with Rinvoq in atopic dermatitis as of 2026
Insilico Medicine / SK Biopharmaceuticalsgaining on$2.5B AI-drug-discovery deal for CNS/neuroimmune targets, June 2026, overlapping AbbVie's neuroscience space
Questions people ask
Is AbbVie profitable in 2026?
Yes. AbbVie posted record FY2025 revenue of $61.16B (up 8.6%) on February 4, 2026, and Q1 2026 revenue hit $15.0B (+12.4% YoY) with adjusted EPS of $2.65, though July 2026 guidance trimmed FY2026 EPS to $13.91-$14.11 versus Street's $14.25.
Is AbbVie losing to Humira biosimilars?
Humira revenue fell 49.5% to $4.5B in FY2025 due to biosimilar erosion, but AbbVie more than offset it: Skyrizi hit $17.6B (+49.9%) and Rinvoq $8.3B, pushing total immunology revenue to $30.4B (+14%) as of February 2026.
Could AI replace AbbVie?
No. AbbVie uses its own ARCH platform (200+ data sources) and partners like Alloy Therapeutics and BigHat for AI-driven drug discovery, but AI cannot obtain FDA approval, secure patents, run manufacturing, or replace payer contracts, the actual moat, as of 2026.
Who is AbbVie's biggest competitor?
In immunology, Sanofi/Regeneron's Dupixent and Eli Lilly's Ebglyss directly rival Skyrizi and Rinvoq, while J&J (Tremfya, Stelara) posted $94.2B in 2025 revenue, larger than AbbVie's $61.2B, per a May 2026 pharma revenue ranking.
Who owns AbbVie?
AbbVie is publicly traded on the NYSE under ABBV with no controlling parent; it spun off from Abbott Laboratories in January 2013 and had a market capitalization of roughly $450 billion as of July 20, 2026.
Will AbbVie's Rinvoq patent cliff hurt future growth?
Rinvoq's core composition patent is expected to expire around 2027, and whether formulation or method-of-use extensions hold is unresolved as of July 2026; Rinvoq generated $8.3B in FY2025 revenue, making the outcome material to AbbVie's immunology growth.
Timeline
  • 2026-07-07FY2026 EPS guidance trimmed to $13.91-$14.11 vs Street's $14.25
  • 2026-06-22Announced acquisition of Apogee Therapeutics for ~$10.9B equity value
  • 2026-03-17Signed antibody-discovery platform deal with Alloy Therapeutics
  • 2026-02-04Reported record FY2025 revenue of $61.16B, up 8.6%
  • 2026-01-12Struck MFN drug-pricing deal with Trump administration, pledged $100B U.S. investment
  • 2025-12-31Employee count reached 57,000, up from 55,000 in 2024
  • 2025-06Acquired Capstan Therapeutics for ~$2.1B for in vivo CAR-T platform
  • 2024Acquired Cerevel Therapeutics and ImmunoGen
  • 2020-05Completed $63B acquisition of Allergan, adding Botox
  • 2013-01AbbVie spun off from Abbott Laboratories, began trading as ABBV
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources